Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of DAPTACEL Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL or Pentacel.

Next Previous
Trial Profile

Safety and Immunogenicity of DAPTACEL Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With DAPTACEL or Pentacel.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi

Most Recent Events

  • 11 May 2010 Actual patient numbers changed from 650 to 649 as reported by ClinicalTrials.gov.
  • 24 Sep 2008 Primary endpoint identified as to provide information concerning the safety of DTaP vaccine as reported by ClinicalTrials.gov
  • 24 Sep 2008 Actual patient number (650) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top